Monday, January 9, 2017

Allergan Announces FDA Acceptance of NDA Filing for Oxymetazoline HCI Cream 1.0%

›
Allergan plc  announced that the New Drug Application (NDA) filing for oxymetazoline HCl cream 1.0%, an investigational topical prescript...
Friday, January 6, 2017

AstraZeneca Receives Complete Response Letter from FDA for Sodium Zirconium Cyclosilicate (ZS-9) for Hyperkalemia

›
AstraZeneca today announced that the US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding the ...
Thursday, January 5, 2017

Lexicon Announces FDA Priority Review of NDA for Telotristat Etiprate for the Treatment of Carcinoid Syndrome

›
Lexicon Pharmaceuticals, Inc.  announced that the U.S. Food and Drug Administration has accepted for filing the New Drug Application for t...
Wednesday, January 4, 2017

Radius Announces FDA Acceptance for Filing of NDA for for the Treatment of Postmenopausal Women with Osteoporosis

›
Radius Health, Inc. ), a science-driven biopharmaceutical company that is committed to developing innovative therapeutics in the areas of ...
Tuesday, January 3, 2017

Teva Announces FDA Approval of ProAir RespiClick (albuterol sulfate) Inhalation Powder for Pediatric Asthma Patients Ages 4 to 11

›
Teva Pharmaceutical Industries Ltd.,  announced  that the U.S. Food and Drug Administration (FDA) has approved ProAir RespiClick (albutero...
Monday, January 2, 2017

Flexion Therapeutics Receives Positive Guidance from FDA on NDA Submission for Zilretta for Osteoarthritis of the Knee

›
Flexion Therapeutics, Inc. announces that yesterday it received written responses from the U.S. Food & Drug Administration (FDA) to qu...
Friday, December 30, 2016

Allergan Receives FDA Approval of Teflaro (ceftaroline fosamil) for Pediatric Patients

›
Allergan plc, a leading global pharmaceutical company,  announced the U.S. Food and Drug Administration (FDA) has approved the company...
Thursday, December 29, 2016

Allergan Announces FDA Approval of Byvalson (nebivolol and valsartan) for Hypertension

›
In continuation of my update on  nebivolol and valsartan Allergan plc (NYSE: AGN), a leading global pharmaceutical company,  announced t...
Wednesday, December 28, 2016

Metabolite of oral DMF drug for multiple sclerosis appears to slow onset of Parkinson's disease

›
In continuation of my update on dimethylfumarate   The metabolite of a drug that is helping patients battle multiple sclerosis appears...
Tuesday, December 27, 2016

Researchers identify promising new compound for targeting triple-negative breast cancer

›
Researchers at the University of Michigan have identified a promising new compound for targeting one of the most aggressive types of breas...
Monday, December 26, 2016

Drug candidate delivered by plant-virus-based carrier shows promise for triple-negative breast cancer

›
In continuation of my update on phenanthriplatin In a pair of firsts, researchers at Case Western Reserve University and Massachusetts...
Friday, December 23, 2016

One-third of osteoporotic women taking oral bisphosphonates have elevated risk for bone fracture

›
Chemical structure of pyrophosphate (A, above) and bisphosphonates (B, below). P = phosphorus, O = oxygen, H = hydrogen, C = carbon, R...
Thursday, December 22, 2016

Maintenance lenalidomide treatment improves overall survival in multiple myeloma patients

›
In continuation of my update on  lenalidomide     lenalidomide   While several clinical trials have demonstrated that maintena...
Wednesday, December 21, 2016

Targeted therapy rucaparib shows promise in treating pancreatic cancer patients with BRCA mutation

›
The targeted therapy rucaparib, which has demonstrated robust clinical activity in ovarian cancer patients with a BRCA mutation, also show...
Tuesday, December 20, 2016

Metformin along with chemotherapy/radiation improves outcomes in head and neck cancer patients

›
In continuation of my update on  metformin Researchers at the University of Cincinnati (UC) College of Medicine have found tha...